{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:16Z","timestamp":1790912476460,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.leukres.2020.106458","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T18:42:20Z","timestamp":1601404940000},"page":"106458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":142,"special_numbering":"C","title":["The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9722-7863","authenticated-orcid":false,"given":"Paul W.","family":"Manley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Barys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra W.","family":"Cowan-Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2020.106458_bib0005","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2147\/DDDT.S191303","article-title":"Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities","volume":"13","author":"Flis","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.leukres.2020.106458_bib0010","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1\u2013positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106458_bib0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.leukres.2020.106458_bib0020","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.18632\/oncotarget.26837","article-title":"BCR: A promiscuous fusion partner in hematopoietic disorders","volume":"10","author":"Peiris","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2020.106458_bib0025","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/1947601912458584","article-title":"Structure, Regulation, Signaling, and Targeting of Abl Kinases in Cancer","volume":"3","author":"Hantschel","year":"2012","journal-title":"Genes Cancer"},{"key":"10.1016\/j.leukres.2020.106458_bib0030","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.3139re6","article-title":"ABL tyrosine kinases: evolution of function, regulation, and specificity","volume":"3","author":"Colicelli","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.leukres.2020.106458_bib0035","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1021\/jm101506n","article-title":"Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type i inhibitor of the triazole carbothioamide class","volume":"54","author":"Salah","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.leukres.2020.106458_bib0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1242\/jcs.175521","article-title":"Multifunctional Abl kinases in health and disease","volume":"129","author":"Khatri","year":"2016","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.leukres.2020.106458_bib0045","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng.3815","article-title":"Germline mutations in ABL1 cause an autosomal dominant syndrome characterized by congenital heart defects and skeletal malformations","volume":"49","author":"Wang","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2020.106458_bib0050","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","article-title":"Structural basis for the autoinhibition of c-Abl tyrosine kinase","volume":"112","author":"Nagar","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2020.106458_bib0055","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1021\/jacs.7b12430","article-title":"ATP site ligands determine the assembly state of the abelson kinase regulatory core via the activation loop conformation","volume":"140","author":"Sonti","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.leukres.2020.106458_bib0060","series-title":"Topics in Medicinal Chemistry","doi-asserted-by":"crossref","DOI":"10.1007\/7355_2017_5","article-title":"Progress in the discovery of BCR-ABL kinase inhibitors for the treatment of leukemia","author":"Manley","year":"2017"},{"key":"10.1016\/j.leukres.2020.106458_bib0065","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Longterm outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2020.106458_bib0070","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s12288-018-1009-y","article-title":"Chronic myeloid leukemia: long-term outcome data in the imatinib era","volume":"35","author":"Ganesan","year":"2019","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"10.1016\/j.leukres.2020.106458_bib0075","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2020.106458_bib0080","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1182\/blood-2011-08-369017","article-title":"CML: live long and prosper","volume":"118","author":"Larson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106458_bib0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2020.106458_bib0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1389557043487321","article-title":"Bcr-Abl kinase mutations and drug resistance to imatinib (STI571) in chronic myelogenous leukemia","volume":"4","author":"Cowan-Jacob","year":"2004","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.leukres.2020.106458_bib0095","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukemia","volume":"8","author":"Apperley","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2020.106458_bib0100","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.3390\/ijms20246141","article-title":"Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update","volume":"20","author":"Bavaro","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2020.106458_bib0105","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","article-title":"The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2020.106458_bib0110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nchembio760","article-title":"Allosteric inhibitors of Bcr-abl-dependent cell proliferation","volume":"2","author":"Adri\u00e1n","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.leukres.2020.106458_bib0115","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2020.106458_bib0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CCO.0b013e328011a25f","article-title":"Ba\/F3 cells and their use in kinase drug discovery","volume":"19","author":"Warmuth","year":"2007","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.leukres.2020.106458_bib0125","doi-asserted-by":"crossref","first-page":"E4437","DOI":"10.1073\/pnas.1314712110","article-title":"NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors","volume":"110","author":"Skora","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2020.106458_bib0130","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2020.106458_bib0135","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.leukres.2020.106458_bib0140","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chembiol.2010.12.013","article-title":"Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site","volume":"18","author":"Yang","year":"2011","journal-title":"Chem. Biol."},{"issue":"2018","key":"10.1016\/j.leukres.2020.106458_bib0145","first-page":"13","article-title":"IC50 profiling against 320 protein kinases: improving the accuracy of kinase inhibitor selectivity testing","volume":"78 suppl 1","author":"Mueller","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2020.106458_bib0150","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1200\/JCO.2009.26.4945","article-title":"Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia","volume":"28","author":"Laneuville","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106458_bib0155","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41589-018-0077-5","article-title":"Structural and genomic decoding of human and plant myristoylomes reveals a definitive recognition pattern","volume":"14","author":"Castrec","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.leukres.2020.106458_bib0160","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1021\/acschembio.0c00314","article-title":"N-Myristoyltransferase as a Glycine and Lysine Myristoyltransferase in Cancer, Immunity, and Infections","volume":"15","author":"Kosciuk","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.leukres.2020.106458_bib0165","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1128\/MCB.00246-10","article-title":"Myristoylation and membrane binding regulate c-Src stability and kinase activity","volume":"30","author":"Patwardhan","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.leukres.2020.106458_bib0170","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.str.2015.07.007","article-title":"An isoform-specific myristylation switch targets type II PKA holoenzymes to membranes","volume":"23","author":"Zhang","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.leukres.2020.106458_bib0175","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1091\/mbc.E16-08-0622","article-title":"The residue at position 5 of the N-terminal region of Src and Fyn modulates their myristoylation, palmitoylation, and membrane interactions","volume":"27","author":"Gottlieb-Abraham","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.leukres.2020.106458_bib0180","doi-asserted-by":"crossref","first-page":"6950","DOI":"10.1158\/0008-5472.CAN-17-0981","article-title":"Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression","volume":"77","author":"Kim","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2020.106458_bib0185","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/ijms20071760","article-title":"Serine\/threonine protein kinase STK16","volume":"20","author":"Wang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.leukres.2020.106458_bib0190","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.isci.2019.01.010","article-title":"A myristoyl-binding site in the SH3 domain modulates c-Src membrane anchoring","volume":"12","author":"Le Roux","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.leukres.2020.106458_bib0195","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.str.2005.03.012","article-title":"The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation","volume":"13","author":"Cowan-Jacob","year":"2005","journal-title":"Structure"},{"key":"10.1016\/j.leukres.2020.106458_bib0200","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.celrep.2018.09.035","article-title":"A dimerization function in the intrinsically disordered N-terminal region of Src","volume":"25","author":"Spassov","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.leukres.2020.106458_bib0205","doi-asserted-by":"crossref","first-page":"20766","DOI":"10.1074\/jbc.M116.741827","article-title":"Novel biochemical and structural insights into the interaction of myristoylated cargo with Unc119 protein and their release by Arl2\/3","volume":"291","author":"Jaiswal","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2020.106458_bib0210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.devcel.2018.08.012","article-title":"The ciliary machinery is repurposed for t cell immune synapse trafficking of LCK","volume":"47","author":"Stephen","year":"2018","journal-title":"Dev. Cell"},{"key":"10.1016\/j.leukres.2020.106458_bib0215","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2020.106458_bib0220","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/BF02623725","article-title":"Establishment of five human myeloma cell lines","volume":"25","author":"Namba","year":"1989","journal-title":"In Vitro Cell. Dev. Biol."},{"key":"10.1016\/j.leukres.2020.106458_bib0225","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"New England J. Med."},{"key":"10.1016\/j.leukres.2020.106458_bib0230","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/leu.2016.353","article-title":"Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors","volume":"31","author":"Lee","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2020.106458_bib0235","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/leu.2017.264","article-title":"Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib","volume":"31","author":"Qiang","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2020.106458_bib0240","doi-asserted-by":"crossref","first-page":"19221","DOI":"10.1073\/pnas.1919221117","article-title":"Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase","volume":"117","author":"Hoemberger","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2020.106458_bib0245","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1074\/jbc.RA118.004732","article-title":"Structural insights into the tyrosine phosphorylation\u2013mediated inhibition of SH3 domain\u2013ligand interactions","volume":"294","author":"Mero","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2020.106458_bib0250","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jmb.2011.04.046","article-title":"Crystal structure of a rigid four-spectrin-repeat fragment of the human Desmoplakin plakin domain","volume":"409","author":"Choi","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.leukres.2020.106458_bib0255","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"AMN107: characterization of a novel inhibitor of both wild-type and imatinib-resistant mutant Bcr-Abl in vitro and in murine models of leukemia","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2020.106458_bib0260","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1021\/acscentsci.7b00211","article-title":"Allosteric communication networks in proteins revealed through pocket crosstalk analysis","volume":"3","author":"La Sala","year":"2017","journal-title":"ACS Central Sci."},{"key":"10.1016\/j.leukres.2020.106458_bib0265","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nsmb.1486","article-title":"Activation of tyrosine kinases by mutation of the gatekeeper threonine","volume":"15","author":"Azam","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.leukres.2020.106458_bib0270","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/ci500060k","article-title":"Insight into the allosteric inhibition of abl kinase","volume":"54","author":"Fallacara","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.leukres.2020.106458_bib0275","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jmgm.2019.03.018","article-title":"Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL","volume":"89","author":"Zhan","year":"2019","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.leukres.2020.106458_bib0280","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.31557\/APJCP.2018.19.12.3317","article-title":"Prevalence of BCR-ABL T315I mutation in malaysian patients with imatinib-resistant chronic myeloid leukemia","volume":"19","author":"Yusoff","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.leukres.2020.106458_bib0285","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.leukres.2020.106458_bib0290","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41375-020-0866-1","article-title":"Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia","volume":"34","author":"Kumar","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2020.106458_bib0295","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.leukres.2020.106458_bib0300","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the Efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"Eadie","year":"2014","journal-title":"Clin. Pharm. Ther."},{"issue":"13","key":"10.1016\/j.leukres.2020.106458_bib0305","article-title":"ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells","volume":"2018","author":"Eadie","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2020.106458_bib0310","doi-asserted-by":"crossref","first-page":"13423","DOI":"10.18632\/oncotarget.24393","article-title":"The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro","volume":"9","author":"Eadie","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2020.106458_bib0315","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","article-title":"Chronic myeloid leukemia, version 1.2019: clinical practice guidelines in oncology","volume":"16","author":"Radich","year":"2018","journal-title":"Natl. Compr. Canc. Netw."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620301636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620301636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:50Z","timestamp":1758934850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212620301636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":63,"alternative-id":["S0145212620301636"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106458","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106458"}}